Albumin-based drug delivery using cysteine 34 chemical conjugates – important considerations and requirements. (July 2017)

• Record Type: Journal Article
• Authors: Caspersen, Mikael B; Kuhlmann, Matthias; Nicholls, Karl; Saxton, Malcolm J; Andersen, Birgitte; Bunting, Karen; Cameron, Jason; Howard, Kenneth A
• Is Part Of: Therapeutic delivery. Volume 8:Number 7(2017)
• Page Start: 511
• Page End: 519
• Publication Date: 2017-07
• Subjects: albumin -- conjugation -- cysteine 34 -- half-life extension -- in vivo models -- neonatal Fc receptor; Drug delivery systems -- Periodicals; Therapeutics -- Periodicals; 615.6
• DOI: 10.4155/tde-2017-0038
• Languages: English
• ISSNs: 2041-5990

Abstract

The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.